Haloperidol Lp Hikma (Haloperidol Decanoate)

Haloperidol decanoate administered intravenously is indicated for the treatment of certain severe psychiatric disorders where long‑acting antipsychotic control is desired, particularly when oral formulations are not feasible or adherence is a concern.

• Schizophrenia with prominent positive symptoms.
• Acute psychotic episodes unresponsive to oral therapy.
• Maintenance therapy to prevent relapse in stabilized patients.
• Adjunctive treatment in patients with treatment‑resistant psychosis.
• Situations where rapid plasma levels are required, such as during hospitalization.
• Acute agitation in emergency settings where rapid onset of antipsychotic effect is required.

Side effects associated with haloperidol decanoate reflect its dopamine antagonism and can vary in frequency and severity, ranging from mild, transient symptoms to rare, serious conditions.

Common

• Sedation or drowsiness, which may affect alertness and daily activities.
• Extrapyramidal symptoms such as mild tremor, rigidity, or akathisia.
• Dry mouth, constipation, and reduced gastrointestinal motility.
• Orthostatic hypotension causing dizziness or light‑headedness upon standing.

Serious

• Neuroleptic malignant syndrome, a rare but potentially life‑threatening reaction characterized by fever, muscle rigidity, and autonomic instability.
• Tardive dyskinesia, presenting as persistent involuntary movements of the face, tongue, or limbs after prolonged use.
• Severe hypotension or cardiac arrhythmias that may require immediate medical attention.
• Hyperprolactinemia leading to hormonal disturbances such as galactorrhea, menstrual irregularities, or sexual dysfunction.

When prescribing haloperidol decanoate, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse outcomes.

• Assess for a history of cardiovascular disease, arrhythmias, or uncontrolled hypertension.
• Use caution in patients with a known sensitivity to butyrophenones or other antipsychotics.
• Monitor for signs of extrapyramidal reactions, especially during the initial weeks of therapy.
• Evaluate liver and renal function periodically, as impairment may affect drug clearance.
• Consider the potential for prolactin elevation and related endocrine effects in long‑term use.
• Review concomitant medications that may prolong QT interval or lower seizure threshold.

Haloperidol decanoate can interact with other medicines, influencing its efficacy or safety profile; awareness of these interactions helps guide appropriate co‑administration.

Avoid

• Concomitant use with other potent dopamine antagonists, which may intensify central nervous system depression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma concentrations.
• Medications that significantly prolong the QT interval, increasing the risk of cardiac arrhythmias.

Use with caution

• CNS depressants such as benzodiazepines or opioids, which may enhance sedation.
• Anticholinergic agents that can mask extrapyramidal symptoms.
• Drugs that affect hepatic metabolism (e.g., carbamazepine) potentially reducing haloperidol levels.